Article
Biochemistry & Molecular Biology
Aron Bartha, Zsuzsanna Darula, Gyoengyi Munkacsy, Eva Klement, Peter Nyirady, Balazs Gyorffy
Summary: This research used a proteotranscriptomic approach to differentiate normal and tumor tissues in clear cell renal cell carcinoma (ccRCC). Top genes over-expressed in ccRCC were identified using transcriptomic data of patients with malignant and normal tissue samples. Protein level analysis and mass spectrometry further validated the differential protein abundance of these genes. A minimal panel of proteins highly specific for ccRCC tissues was identified using transcriptomic and proteomic data.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Fan Zhang, Junyu Lin, Dechao Feng, Jiayu Liang, Yiping Lu, Zhihong Liu, Xianding Wang
Summary: This study explored the correlation between cuprotosis and clear cell renal cell carcinoma (ccRCC) and developed a cuprotosis-related signature to predict the prognosis of patients with ccRCC. The signature risk score was significantly associated with tumor stage, histological grade, and immune cell infiltrates in ccRCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Zuhu Yu, Chong Lu, Bin Lu, Hong Gao, Rongfang Liang, Wuxing Xiang
Summary: This study identified necroptosis-related microRNAs (miRNAs) associated with the prognosis of clear cell renal cell carcinoma (ccRCC), and developed a prognostic signature to predict overall survival in ccRCC patients. The targeted genes of these miRNAs were predicted using miRNA databases, and their functional and pathway associations with ccRCC prognosis were investigated. The differential expression of the three miRNAs in the signature was validated in ccRCC tissues.
Article
Multidisciplinary Sciences
Kangsan Kim, Qinbo Zhou, Alana Christie, Christina Stevens, Yuanqing Ma, Oreoluwa Onabolu, Suneetha Chintalapati, Tiffani Mckenzie, Vanina Toffessi Tcheuyap, Layton Woolford, He Zhang, Nirmish Singla, Pravat Kumar Parida, Mauricio Marquez-Palencia, Ivan Pedrosa, Vitaly Margulis, Arthur Sagalowsky, Zhiqun Xie, Tao Wang, Steffen Durinck, Zora Modrusan, Somasekar Seshagiri, Payal Kapur, James Brugarolas, Srinivas Malladi
Summary: In this study, the authors explore the determinants of vascular invasion and metastasis in RCC patients with tumor thrombi (TT). They found that tumor thrombi associated with metastases are characterized by higher grade, mTOR activation, and a particular immune contexture. TT grade is a better predictor of metastasis than overall tumor grade.
NATURE COMMUNICATIONS
(2021)
Article
Genetics & Heredity
You Zuo, Shuai Fu, Zhongwei Zhao, Zeyan Li, Yijian Wu, Tienan Qi, Jianguo Zheng, Qinglong Du, Zhonghua Xu, Nengwang Yu
Summary: This study constructed a sarcomatoid-associated gene risk index (SAGRI) to predict the prognosis of renal cell carcinoma and found that SAGRI has a high predictive power. The study also suggested that the SAGRI-HIGH subgroup may benefit from immunotherapy.
FRONTIERS IN GENETICS
(2022)
Article
Biochemistry & Molecular Biology
Jing Zhang, Yun Deng, Hui Zhang, Zhiyuan Zhang, Xin Jin, Yan Xuan, Zhen Zhang, Xuejun Ma
Summary: In this study, the role of ferroptosis in the tumor microenvironment of ccRCC was investigated, and 16 immune-related ferroptosis genes (IRFGs) were identified. An IRFG score model was constructed to evaluate its prognostic value in ccRCC patients, and it showed excellent performance in predicting patient survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Xianhui Liu, Weiyu Zhang, Huanrui Wang, Lin Zhu, Kexin Xu
Summary: ACADSB plays an important role in the diagnosis and prognosis of ccRCC. Its downregulation may promote tumorigenesis and tumor progression. The expression level of ACADSB can serve as a significant parameter to discriminate between normal and tumor tissues.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Ke Liang, Yichu Yuan, Bodong Lv, Zunjin Ke
Summary: A 52-year-old male patient was diagnosed with primary renal SCC, which was difficult to diagnose. Surgical treatment was performed and the patient had a good short-term prognosis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell Biology
Yue Wu, Xi Zhang, Xian Wei, Huan Feng, Bintao Hu, Zhiyao Deng, Bo Liu, Yang Luan, Yajun Ruan, Xiaming Liu, Zhuo Liu, Jihong Liu, Tao Wang
Summary: By analyzing differentially expressed ubiquitin-related genes in ccRCC, seven prognostic-related genes were identified and used to construct a predictive signature, which showed good prediction accuracy for evaluating tumor progression in ccRCC patients. The signature was confirmed to be an independent prognostic factor related to the prognosis of ccRCC patients, potentially providing diagnostic and prognostic markers for ccRCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Julia Bohosova, Adela Kubickova, Ondrej Slaby
Summary: PVT1 plays a crucial role in RCC development and there is a significant amount of research trying to uncover its cellular mechanisms. This review summarizes the current knowledge on the role of PVT1 in RCC development and its association with clinical behavior. 17 scientific papers analyzed in this review provide robust support for the importance of PVT1 in RCC development and personalized therapy.
Article
Medicine, Research & Experimental
Liu-xun Chen, Shen-jie Zeng, Xv-dong Liu, Hai-bin Tang, Jia-wu Wang, Qing Jiang
Summary: This study characterizes the intercellular communications within the ccRCC microenvironment and shows their impact on prognosis and immunotherapy efficacy. It reveals a potential relationship between the VHL phenotype and the landscape of cell-cell communication. Moreover, these communication molecules also influence the development and infiltration of T cells and myeloid cells. Different clusters of intercellular communications have significant predictive value for prognosis and distinguish immunotherapy efficiency.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Bin Zheng, Fang Xie, Fajuan Cheng, Jianwei Wang, Zhongshun Yao, Wei He, Zhihong Niu
Summary: This study comprehensively assessed the tumor microenvironment of kidney cancer, identified two immune-related hub genes - IGLL5 and IL2RA, and validated their clinical application value in ccRCC and pRCC. Drug response was also predicted based on selected genes, revealing novel drug candidates for RCC treatment.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Adam Kowalewski, Damian Jaworski, Jedrzej Borowczak, Mateusz Maniewski, Krzysztof Szczerbowski, Paulina Antosik, Justyna Durslewicz, Marta Smolinska, Joanna Ligmanowska, Dariusz Grzanka, Lukasz Szylberg
Summary: Resistance to systemic therapy is a major challenge in the treatment of renal cell carcinoma (RCC). This study explores the connection between TOLLIP expression, tumor characteristics, patient survival, and resistance to therapy in RCC. The findings suggest that TOLLIP may play a role in autophagy-related signaling and contribute to the development of chemoresistance in RCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Yixiao Zhang, Xudong Zhu, Xinbo Qiao, Lisha Sun, Tianhui Xia, Caigang Liu
Summary: The study revealed that HSC70 expression was associated with poor prognosis in ccRCC patients, with those expressing HSC70 having significantly shorter overall survival and higher rates of distant organ metastasis and death. HSC70 may serve as a potential therapeutic target for ccRCC.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Article
Biotechnology & Applied Microbiology
Gang Wang, Fangfang Qu, Shouyong Liu, Jincai Zhou, Yi Wang
Summary: This study revealed that NOP2 might be a potential prognostic factor for overall survival in ccRCC, and it was significantly associated with immunity, MSI, and TMB.
Article
Oncology
Juha P. Virman, Petri Bono, Tiina H. Luukkaala, Kaisa L. Sunela, Paula M. Kujala, Pirkko-Liisa I. Kellokumpu-Lehtinen
CLINICAL GENITOURINARY CANCER
(2016)
Article
Oncology
H. Joensuu, L. Sailas, T. Alanko, K. Sunela, R. Huuhtanen, M. Utriainen, R. Kokko, P. Bono, T. Wigren, S. Pyrhonen, T. Turpeenniemi-Hujanen, R. Asola, M. Leinonen, M. Hahka-Kemppinen, P. Kellokumpu-Lehtinen
ANNALS OF ONCOLOGY
(2010)
Article
Urology & Nephrology
Kaisa L. Sunela, Matti J. Kataja, Pirkko-Liisa I. Kellokumpu-Lehtinen
Article
Oncology
Kaisa Leea Sunela, Sanna Koskinen, Pirkko-Liisa Kellokumpu-Lehtinen
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2010)
Article
Oncology
Kaisa Leea Sunela, Matti Jorma Kataja, Pirkko-Liisa Irmeli Kellokumpu-Lehtinen
CLINICAL GENITOURINARY CANCER
(2013)
Article
Oncology
Aino Rajamaki, Kaisa Sunela, Roosa E. I. Prusila, Milla E. L. Kuusisto, Santiago Mercadal, Tuomas Selander, Hanne Kuitunen, Marjukka Pollari, Esa Jantunen, Ilja Nystrand, Juan-Manuel Sancho, Marc Sorigue, Outi Kuittinen
Summary: The role of sex in follicular lymphoma (FL) remains contradictory, with female patients showing better outcomes in terms of progression-free survival. However, sex does not significantly impact prognosis among patients with early progression of disease (POD). Male sex is identified as an adverse prognostic factor for FL, except in cases of early POD.
LEUKEMIA & LYMPHOMA
(2021)
Article
Urology & Nephrology
Sumanta K. Pal, Javier Puente, Daniel Y. C. Heng, Hilary Glen, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Tudor Ciuleanu, Jae Lyun Lee, Kaisa Sunela, Karen O'Hara, Terri A. Binder, Lixian Peng, Alan D. Smith, Sun Young Rha
Summary: In patients with advanced renal cell carcinoma, a lower starting dose of lenvatinib (14 mg) did not show comparable efficacy to the approved dose (18 mg), although safety results were similar.
Article
Oncology
Aino Rajamaki, Mika Hujo, Reijo Sund, Roosa E. I. Prusila, Milla E. L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen
Summary: This study examined the proportion of deaths from progressive lymphoma and the impact of follicular lymphoma (FL) on survival. The results showed that deaths from progressive lymphoma are nearly as common as deaths from other causes in FL patients during the rituximab era. Despite improvements in survival, there was evidence of excess mortality resulting from FL for at least 10 years after diagnosis.
Article
Oncology
Cristiane Bergerot, Sun Young Rha, Sumanta Pal, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Jae Lyun Lee, Kaisa Sunela, Tudor Ciuleanu, Daniel Heng, Hilary Glen, Jinyi Wang, Lee Bennett, Janice Pan, Karen O'Hara, Javier Puente
Summary: This study focuses on preserving health-related quality of life during renal cell carcinoma treatment. The results showed that patients who received an 18 mg lenvatinib starting dose had better health-related quality of life scores and longer time to deterioration on most scales compared to those who received a 14 mg starting dose. These findings are important for guiding the treatment of renal cell carcinoma.
Article
Oncology
Aino Rajamaki, Hanne Kuitunen, Marc Sorigue, Salla-Maarit Kokkonen, Outi Kuittinen, Kaisa Sunela
Summary: The clinical impact of FDG-PET/CT followed by a new biopsy based on maximum standardized uptake value was evaluated for detecting clinically unsuspected HT of FL. The study results suggest that rebiopsy based on high SUVmax is valuable in detecting clinically unsuspected FL HT.
Letter
Hematology
Aino Rajamaki, Mika Hujo, Reijo Sund, Roosa E. I. Prusila, Milla E. L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan-Manuel Sancho, Outi Kuittinen, Kaisa Sunela
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Oncology
I. Kaartinen, K. Sunela, J. Alanko, K. Hukkinen, M. -L. Karjalainen-Lindsberg, C. Svarvar
Article
Oncology
Juha Virman, Petri Bono, Tiina Luukkaala, Kaisa Sunela, Paula Kujala, Pirkko-Liisa Kellokumpu-Lehtinen
ANTICANCER RESEARCH
(2015)
Article
Oncology
Juha Virman, Ylermi Soini, Paula Kujala, Tiina Luukkaala, Tapio Salminen, Kaisa Sunela, Pirkko-Liisa Kellokumpu-Lehtinen
ANTICANCER RESEARCH
(2014)